Danaher inks $9.6 billion deal for Aldevron
Acquisition to expand presence in genomic medicine
Danaher Corporation, a global science and technology company headquartered in Washington, D.C., has entered into a definitive agreement to acquire privately-held Aldevron for $9.6 billion in cash.
Fargo, ND-based Aldevron, a manufacturer of plasmid DNA, mRNA and proteins that serves clients in the biotech and pharma industries, will still function as a standalone operating company and brand within Danaher's life sciences business, executives say.
"We are thrilled to have Aldevron join Danaher's life sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines,” says Rainer M. Blair, Danaher's president and CEO. “This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster."
